- Home
- PMM vs ACIU Comparison
PMM vs ACIU Comparison
Compare PMM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | ACIU |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.2M | 213.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PMM | ACIU |
|---|---|---|
| Price | $6.14 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 118.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $738.95 |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $1.43 |
| 52 Week High | $6.42 | $4.00 |
Technical Indicators
Market Signals| Indicator | PMM | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 50.19 |
| Support Level | $6.10 | $2.87 |
| Resistance Level | $6.18 | $3.45 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 30.88 | 38.09 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.